phrykt

Coya Therapeutics, Inc. (COYA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of COYA were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Coya Therapeutics

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns COYA

55 funds and institutions reported COYA shares worth $45.5M at the end of Q2 2026, about 33% of the company. The largest holder is DME Capital Management, LP with 10.0%.

Funds and institutions (13F) 33%Everyone else 67%

10 largest owners, by share of the company

DME Capital Management, LP10.0%
Vanguard Capital Management LLC3.6%
Alyeska Investment Group, L.P.3.4%
AIGH Capital Management LLC2.7%
CM Management, LLC1.7%
Private Management Group Inc1.6%
Marshall Wace, LLP1.1%
Geode Capital Management, LLC1.0%
Renaissance Technologies LLC0.8%
Prosight Management, LP0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
DME Capital Management, LP2.34M9.96%$13.7MNo change
Vanguard Capital Management LLC842,2203.59%$4.9M-0%
Alyeska Investment Group, L.P.800,0003.41%$4.7MNo change
AIGH Capital Management LLC631,9122.69%$3.7M-35%
CM Management, LLC400,0001.71%$2.3M+7%
Private Management Group Inc384,2171.64%$2.2M+4%
Marshall Wace, LLP249,7931.06%$1.5M+11%
Geode Capital Management, LLC228,2430.97%$1.3M-2%
Renaissance Technologies LLC192,9860.82%$1.1M+86%
Prosight Management, LP170,0000.72%$994K-60%
Dimensional Fund Advisors LP155,9170.66%$913K+63%
Vanguard Fiduciary Trust Co129,5510.55%$758K-7%
Jones Financial Companies Lllp110,9100.47%$610K+147%
BlackRock, Inc.102,4080.44%$599K+24%
Prelude Capital Management, LLC101,3300.43%$593KNo change
JBF Capital, Inc.100,0060.43%$585KNo change
Royal Bank of Canada93,4140.40%$546K+598%
Morgan Stanley82,1060.35%$480K-4%
State Street Corp79,8130.34%$467KNo change
Susquehanna International Group, LLP61,0060.26%$357K+55%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No COYA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

COYA short interest

Moderate short interest. 6.0% of COYA shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 72%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.41M COYA shares were sold short, 6.0% of the shares outstanding, up 12.4% from the report before. At the average daily volume of 118,633 shares, buying them all back would take about 11.9 trading days (days to cover).

Shares short, % of all shares

6.01%May 15Oct 306.39%

Days to cover

11.9May 15Oct 3013.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.41M6.01%+12%118,63311.9
Oct 15, 20261.25M5.35%+5%145,7818.6
Sep 30, 20261.19M5.08%+0%169,8277.0
Sep 15, 20261.19M5.06%+9%115,97610.2
Aug 31, 20261.09M4.63%+3%94,30711.5
Aug 14, 20261.06M4.51%-1%135,0497.8
Jul 31, 20261.07M4.57%+2%207,1595.2
Jul 15, 20261.05M4.47%+15%298,3043.5
Jun 30, 2026914,9083.90%-8%245,2453.7
Jun 15, 2026990,2274.22%+8%170,3425.8
May 29, 2026919,6733.92%+12%104,0068.8
May 15, 2026818,0973.49%-1%202,9684.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Coya Therapeutics company events

Coya Therapeutics filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 14, 2026AnnouncementCoya Therapeutics, Inc. issued a press release announcing plans to initiate an open-label extension of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis. Filing
  3. Oct 5, 2026AnnouncementCoya Therapeutics, Inc. issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment… Filing
  4. Sep 15, 2026AnnouncementCoya Therapeutics, Inc. issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of… Filing
  5. Aug 11, 2026ResultsReleased financial results. Filing
  6. Aug 7, 2026LeadershipAmended an earlier report. This Amendment No. 1 to Current Report on Form 8-K/A amends the Current Report on Form 8-K of Coya Therapeutics, Inc. dated March 29, 2026 and filed with the Securities and Exchange Commission on April 2, 2026, which disclosed the appointment of Mark H. Pavao to the Board of Directors of the… Filing
  7. Jun 25, 2026VoteReported shareholder vote results. Filing
  8. May 12, 2026AgreementCoya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share, for aggregate gross proceeds of up… Filing
  9. May 12, 2026AnnouncementThe U.S. Food and Drug Administration granted Fast Track Designation to COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS). Filing
  10. Apr 2, 2026LeadershipDr. Howard Berman resigned from the board of directors of Coya Therapeutics, Inc. and from his position as Executive Chairman, each effective as of April 1, 2026. Filing
  11. Mar 16, 2026ResultsReleased financial results. Filing
  12. Jan 30, 2026AgreementCoya Therapeutics, Inc. entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,522,727 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $4.40 per Share. Filing
  13. Jan 20, 2026AnnouncementCoya Therapeutics, Inc. issued a letter to its stockholders wherein it announced its cash balance as of December 31, 2025 was $46.8 million (unaudited) with projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2 trial… Filing
  14. Jan 8, 2026AnnouncementCoya Therapeutics, Inc. issued a press release announcing positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in 9 patients with Frontotemporal Dementia (FTD) over a 6 month period. Filing
  15. Dec 17, 2025AnnouncementCoya Therapeutics, Inc. received a $4.2 million milestone payment under the Development and License Agreement, dated December 5, 2023, by and amongst the Company, Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA. The milestone payment was triggered by dosing of the first… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Coya Therapeutics financials

Famous investors that hold COYA

2 of the 50 well-known investors we track reported holding COYA in their latest 13F filing. The largest position is David Einhorn's, worth $11.7M.

FundQuarterSharesValueOf portfolioChange
David Einhorn · Greenlight Capital (DME)Q3 20262.34M$11.7M0.3%No change
Jim Simons · Renaissance TechnologiesQ3 2026121,800$610K0.0%-37%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Coya Therapeutics, Inc. (COYA) stock

Who owns the most COYA stock?

The largest reported owner of Coya Therapeutics, Inc. (COYA) is DME Capital Management, LP, with 10.0% of the company. In total, 55 funds and institutions reported holding COYA at the end of Q2 2026, together about 33% of the shares. See the largest owners.

Are COYA insiders buying or selling?

No COYA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in COYA?

As of Oct 30, 2026, 1.41M COYA shares were sold short, 6.0% of the shares outstanding, up 12.4% from the report before. At the average daily volume of 118,633 shares, buying them all back would take about 11.9 trading days (days to cover). See the history.

Which famous investors hold COYA?

2 of the 50 well-known investors we track reported COYA in their latest 13F filing, including David Einhorn, Jim Simons. The largest position is worth $11.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.